摘要
目的 探讨小儿肠炎治疗中应用头孢他啶、头孢替安的临床效果差异。方法 选取2013年8月~2016年5月在本院接受诊治112例肠炎患儿进行回顾性分析,根据治疗过程中应用的抗生素分为头孢他啶组60例、头孢替安组52例,头孢他啶组与头孢替安组患儿的补液、纠正电解质紊乱等基础治疗一致,对比临床效果差异。结果 治疗3 d、5 d后,头孢他啶组的大便次数显著的低于头孢替安组（P〈0.05）;头孢他啶组的腹泻持续时间、大便白细胞恢复正常时间均显著的低于头孢替安组（P〈0.05）;治疗3 d后,头孢他啶组的血清CRP、PCT水平均显著的低于头孢替安组（P〈0.05）;头孢他啶组与头孢替安组患儿的血清CRP、PCT水平较治疗前均显著的降低（P〈0.05）;治疗5 d后,头孢他啶组的显效率58.33%、有效率41.67%、无效率0%,头孢替安组的显效率为42.31%、有效率53.85%、无效率3.85%,头孢他啶组的治疗效果优于头孢替安组（P〈0.05）。结论 小儿肠炎治疗中应用头孢他啶效果可靠,安全性高。
Objective To investigate the clinical effect of the application of the clinical effect of the use of lamivudine and the safety in the reatment of infantile enteritis. Methods From August 2013 to May 2016 in our hospital for d i a g n o s i s and trea t m e n t o f 112 cases of enteritis were etrospectively analyzed, according to the application in the treatment of antibiotics into ceftazidime group in 60 cases, cefotiam group 52 cases, two roups of children with rehydration, correct electrolyte disorders such as basic treatment, the difference of clinical effect comparison. Results A f t e r 3 d reatment, ceftazidime group stool frequency was significantly lower than that of cefotiam group （ P 〈 0. 05 ） ; c e f t a z i d i m e g r o u p t h e d u r a t i o n of d i a r r h e a , tool leukocyte recovery time were significantly lower than cefotiam group （ P 〈 0. 05 ） ; t h r e e d a y , five d a y after t r e a t m e n t o f s e r u m CRP, PCT levels w e r e eftazidime group significantly lower than cefotiam group （P 〈 0. 05 ） ; t h e t w o g r o u p s o f s e r u m CRP a n d PCT levels b e f o r e t r e a t m e n t w e r e significantly ecreased （F〈0. 05） ; After five days treatment, 5D after treatment, ceftazidime group the effective rate of 58. 33% , effective 41. 67%,invalid rate % , cefotiam group the effective rate was 42. 31% , effective 53. 85% , invalid rate 3. 85% , ceftazidime treatment group is better than that of cefotiam roup （F〈0. 05）. Conclusion In t he treatment of infantile enteritis, the effect is reliable and t he safety is high.
出处
《中国生化药物杂志》
CAS
2017年第4期333-335,共3页
Chinese Journal of Biochemical Pharmaceutics
